Skip to main content
Caplight Logo









Irazu Oncology

Irazu Oncology

Private
Baltimore, MarylandHealthcare & Life Scienceshttps://www.irazuoncology.com/

Last Round

Seed

Jul 7, 2026

Total Funding Raised

$3.15M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Irazu Oncology is a biotechnology company that develops next-generation cancer immunotherapies using a proprietary Outer Membrane Vesicles (OMV) platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

OMVouter membrane vesiclecancer immunotherapycancer vaccinetherapeutic vaccinesolid tumor treatmentbacterial nanoparticleoff-the-shelf vaccinebiotech startupdrug discoveryIND-enabling studiesantigen deliverynext-gen oncologybacterial platformpreclinical biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Irazu Oncology Comparables

Compare Irazu Oncology with similar companies based on industry and business-model similarity.

Irazu Oncology comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Baccine Ltd.
82%
EV Therapeutics
81%
BiOMViS Srl
80%

Irazu Oncology Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedJul 7, 2026
VC RoundMar 4, 2025
Series AMar 4, 2025
SeedDec 19, 2023
GrantAug 28, 2023

Key People

Founding team and executive leadership

Jeffrey Strovel

Chief Executive Officer

Executive Team

Irazu Oncology Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 19, 2026

    Monthly visitors grew 50% MoM to 1.3K.

  • Mar 4, 2025

    $500K round led by TEDCO.

Recent news

Latest coverage and updates

  • receives_financingJul 7, 2026

    Irazu Oncology, LLC received financing of $250K in investment on Jul 7th '26.

Irazu Oncology Filings

Explore SEC and related filing metadata, where available.

Irazu Oncology filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Irazu Oncology's valuation, stock price, and market status.

Is Irazu Oncology a public or private company?

Irazu Oncology is a private company.

What is the current stock price of Irazu Oncology?

Irazu Oncology is a private company with no public stock price. No recent secondary market data is available.

How much is Irazu Oncology worth (valuation)?

Valuation information for Irazu Oncology is not publicly available.

Can I buy Irazu Oncology stock?

Irazu Oncology shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Irazu Oncology's last funding round?

Irazu Oncology's most recent funding round was VC Round on March 4, 2025.

Who are the main investors in Irazu Oncology?

Key investors in Irazu Oncology include Wexford Science & Technology.

Will Irazu Oncology IPO soon?

No public IPO plans have been announced for Irazu Oncology.

How can I track Irazu Oncology secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Irazu Oncology's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBaltimore, Maryland
Employee Range11
Year Founded2022
Last FundingJul 7, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?